Last patient visit complete in VIA Pharmaceuticals' Phase 2 FDG-PET trial

VIA Pharmaceuticals, Inc. (Nasdaq: VIAP), a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that it has completed the last patient visit in its Phase 2 FDG-PET clinical trial of VIA-2291.

The FDG-PET trial enrolled 52 patients and was carried out at five sites in the US and Canada including Massachusetts General Hospital, Mount Sinai School of Medicine, University of Massachusetts, Winthrop University Hospital and Montreal Heart Institute. The study is designed to measure the impact of VIA-2291 on reducing inflammation in carotid plaque in treated patients. Patients were enrolled following an acute coronary syndrome event, such as heart attack or stroke, into the 24 week, randomized, double blind, placebo-controlled study. Endpoints in the study include reduction in atherosclerotic plaque inflammation as measured by serial FDG-PET scans. Completion of the data analysis and presentation of clinical trial results are anticipated in early 2010.